1. Ficha Técnica Fabroven

2. Pouget G, Ducros L, Marcelon G. Effect of Ruscus extract on peripheral lymphatic vessel pressure and flow. In P. Vanhoutte, Editor. Return circulation and norepinephrine: an update. John Libbey Eurotext, Paris 1991, 89-95.

3. Kakkos SK, Guex JJ, Lugli M, Nicolaides AN. CEAP clinical classes C0S-C4: differences, similarities and role of Ruscus + HMC + vitamin C in patients with chronic venous disease.Int Angiol. 2020;39(2):118-124.

4. Monjotin N, Tenca G. Lymphotonic activity of Ruscus extract, hesperidin methyl chalcone and vitamin C in human lymphatic smooth muscle cells. Microvasc Res. 2022;139:104274.

5. Rauly-Lestienne I, Heusler P, Cussac D, et al. Contribution of muscarinic receptors to in vitro and in vivo effects of Ruscus extract. Microvasc Res. 2017;114:1-11.

6. Bouskela E, Cyrino FZ, Marcelon G. Inhibitory effect of the Ruscus extract and of the flavonoid hesperidine methylchalcone on increased microvascular permeability induced by various agents in the hamster cheek pouch. J Cardiovasc Pharmacol. 1993;22(2):225-230.

7. Kvasnicka T, Zemanova IH, Granova B, et al. Monitoring the clinical effect of the Cyclo 3 Fort® venopharmaceutical in patients with venous insufficiency (SEVEC study). Medicína. 2020.

8. Guex JJ, Enriquez Vega DM, Avril L, et al. Assessment of quality of life in Mexican patients suffering from chronic venous disorder - impact of oral Ruscus aculeatus-hesperidinmethyl-chalcone-ascorbic acid treatment - 'QUALITY Study'. Phlebology. 2009;24(4):157-165.

9. Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37(3):181-254.